Literature DB >> 29276655

Polypoidal Choroidal Vasculopathy.

Joon-Bom Kim1, Rajinder S Nirwan1, Ajay E Kuriyan1.   

Abstract

PURPOSE OF REVIEW: The goal of this paper is to review the recent literature of polypoidal choroidal vasculopathy (PCV) and provide an update on the epidemiology, pathophysiology, clinical findings, and management. RECENT
FINDINGS: Although indocyanine-green angiography (ICGA) is still the gold standard for diagnosis of PCV, the use of en face optical coherence tomography (OCT) and OCT angiography are useful tools in the diagnosis of PCV. Studies demonstrate superior treatment outcomes with combination photodynamic therapy (PDT) and anti-vascular endothelial growth factor (VEGF) therapy.
SUMMARY: PCV is a disease most commonly in Asians and African-Americans and presents with an orange-red nodule in the macula or the peripapillary region. While ICGA remains the most accurate method to diagnose PCV, newer non-invasive imaging modalities (eg. OCT-A and en face OCT) can be used to identify PCV lesions. The combination of PDT and anti-VEGF therapy is superior to either monotherapy. Future studies of OCT modalities and other anti-VEGF agents will be important in guiding PCV diagnosis and management, respectively.

Entities:  

Keywords:  age-related macular degeneration; choroidal neovascularization; ophthalmology; polypoidal choroidal vasculopathy

Year:  2017        PMID: 29276655      PMCID: PMC5736141          DOI: 10.1007/s40135-017-0137-0

Source DB:  PubMed          Journal:  Curr Ophthalmol Rep        ISSN: 2167-4868


  157 in total

1.  Photodynamic therapy for polypoidal choroidal vasculopathy: vaso-occlusive effect on the branching vascular network and origin of recurrence.

Authors:  Won Ki Lee; Phil Young Lee; Sang Kyu Lee
Journal:  Jpn J Ophthalmol       Date:  2008-04-30       Impact factor: 2.447

2.  LOC387715/HTRA1 variants and the response to combined photodynamic therapy with intravitreal bevacizumab for polypoidal choroidal vasculopathy.

Authors:  Dong Ho Park; In Taek Kim
Journal:  Retina       Date:  2012-02       Impact factor: 4.256

3.  Punctate hyperfluorescent spots associated with polypoidal choroidal vasculopathy on indocyanine green angiography.

Authors:  Hyesun Kim; Ji Hwan Lee; Kye Yoon Kwon; Suk Ho Byeon; Sung Chul Lee; Christopher Seungkyu Lee
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2015-04       Impact factor: 1.300

4.  LAPTOP study: a 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathy.

Authors:  Akio Oishi; Noriko Miyamoto; Michiko Mandai; Shigeru Honda; Toshiyuki Matsuoka; Hideyasu Oh; Mihori Kita; Tomoko Nagai; Nobuhiro Bessho; Mamoru Uenishi; Yasuo Kurimoto; Akira Negi
Journal:  Ophthalmology       Date:  2014-01-29       Impact factor: 12.079

5.  Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy.

Authors:  Salih Uzun; Emre Pehlivan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-27       Impact factor: 3.117

6.  Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor.

Authors:  Ursula Schmidt-Erfurth; Ursula Schlötzer-Schrehard; Claus Cursiefen; Stephan Michels; Arne Beckendorf; Gottfried O H Naumann
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-10       Impact factor: 4.799

7.  A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration.

Authors:  Atsuhiro Kanda; Wei Chen; Mohammad Othman; Kari E H Branham; Matthew Brooks; Ritu Khanna; Shirley He; Robert Lyons; Gonçalo R Abecasis; Anand Swaroop
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-20       Impact factor: 11.205

8.  Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Yasuhiko Hirami; Akitaka Tsujikawa; Atsushi Otani; Yuko Yodoi; Hiroko Aikawa; Michiko Mandai; Nagahisa Yoshimura
Journal:  Retina       Date:  2007-03       Impact factor: 4.256

9.  Systemic risk factors associated with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration.

Authors:  Yoichi Sakurada; Seigo Yoneyama; Mitsuhiro Imasawa; Hiroyuki Iijima
Journal:  Retina       Date:  2013-04       Impact factor: 4.256

10.  One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients.

Authors:  Fumi Gomi; Masahito Ohji; Kaori Sayanagi; Miki Sawa; Hirokazu Sakaguchi; Yusuke Oshima; Yasushi Ikuno; Yasuo Tano
Journal:  Ophthalmology       Date:  2007-06-20       Impact factor: 12.079

View more
  5 in total

1.  [Stressed country doctor with acute visual loss : Clear diagnosis?]

Authors:  D Heinrich; M Ulbig; N Feucht; M Maier
Journal:  Ophthalmologe       Date:  2018-09       Impact factor: 1.059

2.  Application of Deep Learning for Automated Detection of Polypoidal Choroidal Vasculopathy in Spectral Domain Optical Coherence Tomography.

Authors:  Papis Wongchaisuwat; Ranida Thamphithak; Peerakarn Jitpukdee; Nida Wongchaisuwat
Journal:  Transl Vis Sci Technol       Date:  2022-10-03       Impact factor: 3.048

Review 3.  Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes.

Authors:  Thibaud Mathis; Frank G Holz; Sobha Sivaprasad; Young Hee Yoon; Nicole Eter; Lee-Jen Chen; Adrian Koh; Eduardo Cunha de Souza; Giovanni Staurenghi
Journal:  Eye (Lond)       Date:  2022-09-14       Impact factor: 4.456

Review 4.  Polypoidal choroidal vasculopathy: An update on current management and review of literature.

Authors:  Amit Harishchandra Palkar; Vikas Khetan
Journal:  Taiwan J Ophthalmol       Date:  2019 Apr-Jun

5.  Polypoidal Choroidal Vasculopathy in Congolese Patients.

Authors:  Nelly N Kabedi; David L Kayembe; Gloria M Elongo; Jean-Claude Mwanza
Journal:  J Ophthalmol       Date:  2020-01-18       Impact factor: 1.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.